基本信息
浏览量:257
职业迁徙
个人简介
Dr. David Andrews is Director of and Senior Scientist in Biological Sciences at Sunnybrook Research Institute (SRI). He holds a Tier 1 Canada Research Chair in Membrane Biogenesis. His research comprises, the molecular mechanisms by which Bcl-2 family proteins regulate apoptosis, early stage drug discovery, high-content screening and development of new microscopes for fluorescence lifetime imaging microscopy (FLIM) and hyperspectral imaging. Dr. Andrews’ lab uses fluorescence spectroscopy and fluorescence spectroscopic microscopy to study interactions between proteins in membranes using purified proteins, and in live cells. To study cancer, they use primary patient cells grown as 3D organoids for drug screening. At SRI, he has established a facility for image-based high-content cellular analysis that includes instrumentation for automated imaging and analysis of cells in monolayer and 3D cultures, genome scale gene knockdown and screening of libraries of small molecules. In early stage drug discovery research, his lab has identified and characterized small molecules that have applications to cancer and regenerative medicine.
Dr. Andrews is active in the public and private sector. He is a member of several editorial boards, including BMC Molecular and Cell Biology and Cell Death and Differentiation. His lab has collaborated with a number of pharmaceutical companies including Abbott, ABBVIE, Celgene, Eli Lilly, Genentech, Johnson and Johnson, and Novartis. Dr. Andrews is developing a new generation of automated high-speed hyperspectral FLIM confocal and new AI driven software for automated analysis of fluorescence micrographs of cells. FLIM is used to measure protein-protein interactions in live cells. Automated microscopy and machine learning tools are being applied to develop new personalized medicine approaches for diseases including chronic lymphocytic leukemia, ovarian cancer and breast cancer.
Dr. Andrews is active in the public and private sector. He is a member of several editorial boards, including BMC Molecular and Cell Biology and Cell Death and Differentiation. His lab has collaborated with a number of pharmaceutical companies including Abbott, ABBVIE, Celgene, Eli Lilly, Genentech, Johnson and Johnson, and Novartis. Dr. Andrews is developing a new generation of automated high-speed hyperspectral FLIM confocal and new AI driven software for automated analysis of fluorescence micrographs of cells. FLIM is used to measure protein-protein interactions in live cells. Automated microscopy and machine learning tools are being applied to develop new personalized medicine approaches for diseases including chronic lymphocytic leukemia, ovarian cancer and breast cancer.
研究兴趣
论文共 94 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
HEARTno. 18 (2020): 1427-1431
Michael P. Baldassari, Donald Yandong Ye, Clifford Yudkoff, Allison Doermann, Tyler Henry,James J. Evans,David W. Andrews,Christopher J. Farrell,Kevin D. Judy
引用0浏览0引用
0
0
A.J. Song, S. Gowda,Lyndon Kim,Maria Werner-Wasik,David W. Andrews,Jon Glass,Kevin Judy,Christopher J. Farrell,Wenyin Shi
PANCREASno. 7 (2017): 954-954
引用0浏览0引用
0
0
引用23浏览0引用
23
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn